Come up with a name for your new list and we'll add to it:
Atopix Therapeutics raised a round of funding on June 17, 2015. Investors include
Silicon Valley Bank.
Atopix Therapeutics is a privately held clinical-stage biopharmaceutical company that is developing a class of oral anti-allergic medicines, called CRTH2 antagonists, to treat atopic dermatitis, asthm…